AKLI logo

Akili, Inc. Stock Price

NasdaqCM:AKLI Community·US$34.0m Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 0 Fair Values set on narratives written by author

AKLI Share Price Performance

US$0
0.00 (0.00%)
US$0
0.00 (0.00%)
Price US$0

AKLI Community Narratives

There are no narratives available yet.

Trending Discussion

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Excellent balance sheet with limited growth.

3 Risks
1 Reward

Akili, Inc. Key Details

US$1.9m

Revenue

US$855.0k

Cost of Revenue

US$1.1m

Gross Profit

US$49.6m

Other Expenses

-US$48.5m

Earnings

Last Reported Earnings
Mar 31, 2024
Next Reporting Earnings
n/a
-0.62
56.11%
-2,492.04%
22.5%
View Full Analysis

About AKLI

Founded
2011
Employees
68
CEO
Matthew Franklin
WebsiteView website
www.akiliinteractive.com

Akili, Inc., a digital medicine company, develops cognitive treatments through game-changing technologies. The company provides EndeavorRx, a computer-based testing for cognitive dysfunction across several neurology and psychiatry indications, including attention-deficit hyperactivity disorder, depressive disorder, autism spectrum disorder, multiple sclerosis, and other neuroinflammatory diseases. It also offers selective stimulus management engine mechanism to activate the fronto-parietal cortex area in the brain; body brain trainer for attention, impulsivity, working memory, and goal management; and spatial navigation engine for spatial navigation, memory, and planning and organization. The company was founded in 2011 and is headquartered in Boston, Massachusetts.

Recent AKLI News & Updates

Recent updates

No updates